Kane Biotech Stock Performance
| KNBIF Stock | USD 0.03 0 6.96% |
On a scale of 0 to 100, Kane Biotech holds a performance score of 9. The company secures a Beta (Market Risk) of 0.76, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Kane Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding Kane Biotech is expected to be smaller as well. Please check Kane Biotech's semi variance, day typical price, and the relationship between the value at risk and kurtosis , to make a quick decision on whether Kane Biotech's current price movements will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Kane Biotech are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite nearly weak forward indicators, Kane Biotech reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 1 M | |
| Total Cashflows From Investing Activities | -373.5 K |
Kane |
Kane Biotech Relative Risk vs. Return Landscape
If you would invest 2.18 in Kane Biotech on November 5, 2025 and sell it today you would earn a total of 0.76 from holding Kane Biotech or generate 34.86% return on investment over 90 days. Kane Biotech is currently producing 0.5905% returns and takes up 4.7479% volatility of returns over 90 trading days. Put another way, 42% of traded pink sheets are less volatile than Kane, and 89% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Kane Biotech Target Price Odds to finish over Current Price
The tendency of Kane Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.03 | 90 days | 0.03 | about 11.13 |
Based on a normal probability distribution, the odds of Kane Biotech to move above the current price in 90 days from now is about 11.13 (This Kane Biotech probability density function shows the probability of Kane Pink Sheet to fall within a particular range of prices over 90 days) .
Kane Biotech Price Density |
| Price |
Predictive Modules for Kane Biotech
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Kane Biotech. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Kane Biotech Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Kane Biotech is not an exception. The market had few large corrections towards the Kane Biotech's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Kane Biotech, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Kane Biotech within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.13 | |
β | Beta against Dow Jones | 0.76 | |
σ | Overall volatility | 0 | |
Ir | Information ratio | 0.02 |
Kane Biotech Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Kane Biotech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Kane Biotech can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Kane Biotech has some characteristics of a very speculative penny stock | |
| Kane Biotech appears to be risky and price may revert if volatility continues | |
| Kane Biotech has accumulated 1.12 M in total debt with debt to equity ratio (D/E) of 7.12, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Kane Biotech has a current ratio of 0.66, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Kane Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Kane Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Kane Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Kane to invest in growth at high rates of return. When we think about Kane Biotech's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 1.61 M. Net Loss for the year was (4.6 M) with profit before overhead, payroll, taxes, and interest of 568.44 K. | |
| Kane Biotech has accumulated about 2.53 M in cash with (2.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02. | |
| Roughly 27.0% of Kane Biotech outstanding shares are owned by corporate insiders |
Kane Biotech Fundamentals Growth
Kane Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Kane Biotech, and Kane Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Kane Pink Sheet performance.
| Return On Equity | -5.97 | |||
| Return On Asset | -0.39 | |||
| Profit Margin | (1.80) % | |||
| Operating Margin | (1.72) % | |||
| Current Valuation | 12.47 M | |||
| Shares Outstanding | 124.83 M | |||
| Price To Earning | 4.68 X | |||
| Price To Book | 102.61 X | |||
| Price To Sales | 3.45 X | |||
| Revenue | 1.61 M | |||
| EBITDA | (4.25 M) | |||
| Cash And Equivalents | 2.53 M | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 1.12 M | |||
| Debt To Equity | 7.12 % | |||
| Book Value Per Share | (0.05) X | |||
| Cash Flow From Operations | (2.29 M) | |||
| Earnings Per Share | (0.03) X | |||
| Total Asset | 6.13 M | |||
About Kane Biotech Performance
By analyzing Kane Biotech's fundamental ratios, stakeholders can gain valuable insights into Kane Biotech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Kane Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Kane Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada. Kane Biotech is traded on OTC Exchange in the United States.Things to note about Kane Biotech performance evaluation
Checking the ongoing alerts about Kane Biotech for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Kane Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Kane Biotech has some characteristics of a very speculative penny stock | |
| Kane Biotech appears to be risky and price may revert if volatility continues | |
| Kane Biotech has accumulated 1.12 M in total debt with debt to equity ratio (D/E) of 7.12, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Kane Biotech has a current ratio of 0.66, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Kane Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Kane Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Kane Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Kane to invest in growth at high rates of return. When we think about Kane Biotech's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 1.61 M. Net Loss for the year was (4.6 M) with profit before overhead, payroll, taxes, and interest of 568.44 K. | |
| Kane Biotech has accumulated about 2.53 M in cash with (2.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02. | |
| Roughly 27.0% of Kane Biotech outstanding shares are owned by corporate insiders |
- Analyzing Kane Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Kane Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Kane Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Kane Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Kane Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Kane Biotech's pink sheet. These opinions can provide insight into Kane Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Kane Pink Sheet analysis
When running Kane Biotech's price analysis, check to measure Kane Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kane Biotech is operating at the current time. Most of Kane Biotech's value examination focuses on studying past and present price action to predict the probability of Kane Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kane Biotech's price. Additionally, you may evaluate how the addition of Kane Biotech to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |